Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
OKYO Pharma Limited Sponsored ADR (OKYO)
NASDAQ:OKYO
RESEARCH TOOLSreports
Holding OKYO?
Track your performance easily
OKYO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.81 - $2.12
Previous Close$1.07
Volume59.53K
Average Volume (3M)192.49K
Market Cap
$36.26M
Enterprise Value$35.45M
Total Cash (Recent Filing)£633.63K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Nov 29, 2024EPS Estimate
-$0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding33,840,000
10 Day Avg. Volume52,989
30 Day Avg. Volume192,489
Standard Deviation0.19
R-Squared0.00080
Alpha-0.00191
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$7.00Price Target Upside566.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
OKYO Pharma Limited Sponsored ADR News
PremiumCompany Announcements
OKYO Pharma Advances in Ocular Treatment Trials
PremiumCompany Announcements
OKYO Pharma Begins Key Trial for Eye Pain Therapy
PremiumCompany Announcements
OKYO Pharma Begins Key Phase 2 Trial for Eye Pain Drug
PremiumCompany Announcements
OKYO Pharma Chairman Boosts Stake, Advances Trials
PremiumCompany Announcements
OKYO Pharma Chairman Boosts Stake, Advances TrialsBulls Say, Bears Say
Bulls Say
Clinical Trial SuccessOK-101 has demonstrated favorable safety and tolerability in a Phase 2 trial in dry eye disease, with statistically significant improvements in symptoms such as stinging/burning and ocular pain, indicating strong efficacy potential for broader applications.
Market PotentialNCP represents an urgent unmet medical need and an effective NCP treatment may have significant market prospects, highlighting the commercial opportunity for OK-101.
Regulatory ApprovalOK-101 is the first NCP drug candidate that has received FDA IND clearance for clinical evaluation, which marks a significant milestone and demonstrates its potential in addressing unmet medical needs.
Bears Say
Clinical TrialsFailure of OK-101 in clinical trials poses significant risk for the stock.
Market CompetitionHigh competition and challenges in market penetration may hinder the commercial success of OK-101, affecting the stock's performance.
Regulatory ApprovalInability to secure regulatory approval for OK-101 in the U.S. could negatively impact the stock's prospects.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.04% Mutual Funds
― Other Institutional Investors
99.96% Public Companies and
Individual Investors
OKYO FAQ
What was OKYO Pharma Limited Sponsored ADR’s price range in the past 12 months?
OKYO Pharma Limited Sponsored ADR lowest stock price was $0.81 and its highest was $2.12 in the past 12 months.
What is OKYO Pharma Limited Sponsored ADR’s market cap?
Currently, no data Available
When is OKYO Pharma Limited Sponsored ADR’s upcoming earnings report date?
OKYO Pharma Limited Sponsored ADR’s upcoming earnings report date is Nov 29, 2024 which is in 6 days.
How were OKYO Pharma Limited Sponsored ADR’s earnings last quarter?
Currently, no data Available
Is OKYO Pharma Limited Sponsored ADR overvalued?
According to Wall Street analysts OKYO Pharma Limited Sponsored ADR’s price is currently Undervalued.
Does OKYO Pharma Limited Sponsored ADR pay dividends?
OKYO Pharma Limited Sponsored ADR does not currently pay dividends.
What is OKYO Pharma Limited Sponsored ADR’s EPS estimate?
OKYO Pharma Limited Sponsored ADR’s EPS estimate is -$0.09.
How many shares outstanding does OKYO Pharma Limited Sponsored ADR have?
OKYO Pharma Limited Sponsored ADR has 33,886,314 shares outstanding.
What happened to OKYO Pharma Limited Sponsored ADR’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of OKYO Pharma Limited Sponsored ADR?
Currently, no hedge funds are holding shares in OKYO
---
OKYO Pharma Limited Sponsored ADR Stock Smart Score
Company Description
OKYO Pharma Limited Sponsored ADR
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions on various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
---
OKYO Stock 12 Month Forecast
Average Price Target
$7.00
▲(566.67% Upside)
Technical Analysis
Best Analysts Covering OKYO
1 Year
1 Year Success Rate
1/8 ratings generated profit
1 Year Average Return
-23.82%
reiterated a buy rating last month
Copying Yi Chen's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -23.82% per trade.
---